Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01787994 · ClinicalTrials.gov registry record · Phase 1
Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy
A Phase 1 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01787994: Completed Phase 1 study, sponsored by University of Pennsylvania.
NCT01787994 is a Phase 1 study that has completed, run by University of Pennsylvania. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01787994, a Phase 1 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is an open label, dual cohort study evaluating safety, tolerability and immunogenicity of redirected CD4+ T cells in HIV subjects.
Interventions
- GENETIC Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-12 |
| Est. Completion | 2017-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01787994
The ClinicalTrials.gov registry entry for NCT01787994 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion. is the first listed.
NCT01787994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01787994 about?
NCT01787994 is a clinical study titled "Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy". This is an open label, dual cohort study evaluating safety, tolerability and immunogenicity of redirected CD4+ T cells in HIV subjects.
What is the current status of trial NCT01787994?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2012-12. Estimated completion is 2017-07.
What interventions are being tested in trial NCT01787994?
The interventions under investigation include: Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion. (GENETIC).
Who is sponsoring clinical trial NCT01787994?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.